malaria vaccines

Summary

Summary: Vaccines made from antigens arising from any of the four strains of Plasmodium which cause malaria in humans, or from P. berghei which causes malaria in rodents.

Top Publications

  1. ncbi First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children
    Selidji Todagbe Agnandji
    Albert Schweitzer Hospital, Lambarene, Gabon
    N Engl J Med 365:1863-75. 2011
  2. ncbi A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants
    Selidji Todagbe Agnandji
    Albert Schweitzer Hospital, Lambarene, Gabon
    N Engl J Med 367:2284-95. 2012
  3. pmc Genome sequence of the human malaria parasite Plasmodium falciparum
    Malcolm J Gardner
    The Institute for Genomic Research, 9712 Medical Center Drive, Rockville, Maryland 20850, USA
    Nature 419:498-511. 2002
  4. ncbi Immunity to malaria: more questions than answers
    Jean Langhorne
    Division of Parasitology, National Institute for Medical Research, London NW7 1AA, UK
    Nat Immunol 9:725-32. 2008
  5. pmc A field trial to assess a blood-stage malaria vaccine
    Mahamadou A Thera
    Malaria Research and Training Center, University of Bamako, Bamako, Mali
    N Engl J Med 365:1004-13. 2011
  6. pmc ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans
    Susanne H Sheehy
    Centre for Clinical Vaccinology and Tropical Medicine, The Jenner Institute, University of Oxford, Churchill Hospital, Oxford, UK
    Mol Ther 20:2355-68. 2012
  7. ncbi Protection against a malaria challenge by sporozoite inoculation
    Meta Roestenberg
    Department of Medical Microbiology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands
    N Engl J Med 361:468-77. 2009
  8. pmc Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector
    Geraldine A O'Hara
    Centre for Clinical Vaccinology and Tropical Medicine and the Jenner Institute Laboratories, University of Oxford, UK
    J Infect Dis 205:772-81. 2012
  9. ncbi Live attenuated malaria vaccine designed to protect through hepatic CD8⁺ T cell immunity
    J E Epstein
    U S Military Malaria Vaccine Program, Naval Medical Research Center, Silver Spring, MD 20910, USA
    Science 334:475-80. 2011
  10. pmc Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors
    Susanne H Sheehy
    Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Oxford, United Kingdom
    PLoS ONE 7:e31208. 2012

Detail Information

Publications334 found, 100 shown here

  1. ncbi First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children
    Selidji Todagbe Agnandji
    Albert Schweitzer Hospital, Lambarene, Gabon
    N Engl J Med 365:1863-75. 2011
    ..An ongoing phase 3 study of the efficacy, safety, and immunogenicity of candidate malaria vaccine RTS,S/AS01 is being conducted in seven African countries...
  2. ncbi A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants
    Selidji Todagbe Agnandji
    Albert Schweitzer Hospital, Lambarene, Gabon
    N Engl J Med 367:2284-95. 2012
    ..We studied infants 6 to 12 weeks of age recruited for the same trial...
  3. pmc Genome sequence of the human malaria parasite Plasmodium falciparum
    Malcolm J Gardner
    The Institute for Genomic Research, 9712 Medical Center Drive, Rockville, Maryland 20850, USA
    Nature 419:498-511. 2002
    ..The genome sequence provides the foundation for future studies of this organism, and is being exploited in the search for new drugs and vaccines to fight malaria...
  4. ncbi Immunity to malaria: more questions than answers
    Jean Langhorne
    Division of Parasitology, National Institute for Medical Research, London NW7 1AA, UK
    Nat Immunol 9:725-32. 2008
    ..The main hope for changing this situation would be the development of effective malaria vaccines. An important part of this process is understanding the mechanisms of naturally acquired immunity to malaria...
  5. pmc A field trial to assess a blood-stage malaria vaccine
    Mahamadou A Thera
    Malaria Research and Training Center, University of Bamako, Bamako, Mali
    N Engl J Med 365:1004-13. 2011
    Blood-stage malaria vaccines are intended to prevent clinical disease. The malaria vaccine FMP2...
  6. pmc ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans
    Susanne H Sheehy
    Centre for Clinical Vaccinology and Tropical Medicine, The Jenner Institute, University of Oxford, Churchill Hospital, Oxford, UK
    Mol Ther 20:2355-68. 2012
    ..The blood-stage malaria vaccines were administered alone, or together (MSP1+AMA1), or with a pre-erythrocytic malaria vaccine candidate (MSP1+..
  7. ncbi Protection against a malaria challenge by sporozoite inoculation
    Meta Roestenberg
    Department of Medical Microbiology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands
    N Engl J Med 361:468-77. 2009
    ..Naturally acquired immunity to malaria develops slowly, and induction of protection in humans can be achieved artificially by the inoculation of radiation-attenuated sporozoites by means of more than 1000 infective mosquito bites...
  8. pmc Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector
    Geraldine A O'Hara
    Centre for Clinical Vaccinology and Tropical Medicine and the Jenner Institute Laboratories, University of Oxford, UK
    J Infect Dis 205:772-81. 2012
    ..Use of potently immunogenic human adenoviruses as vaccine vectors could overcome this problem, but these are limited by preexisting immunity to human adenoviruses...
  9. ncbi Live attenuated malaria vaccine designed to protect through hepatic CD8⁺ T cell immunity
    J E Epstein
    U S Military Malaria Vaccine Program, Naval Medical Research Center, Silver Spring, MD 20910, USA
    Science 334:475-80. 2011
    ..Our results suggest that intravenous administration of this vaccine will lead to the prevention of infection with Pf malaria...
  10. pmc Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors
    Susanne H Sheehy
    Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Oxford, United Kingdom
    PLoS ONE 7:e31208. 2012
    ..falciparum. The development of a vaccine that could induce both cell-mediated and humoral immune responses would enable important proof-of-concept efficacy studies to be undertaken to address this question...
  11. ncbi Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection
    Kent E Kester
    Walter Reed Army Institute of Research, 503 Robert Grant Ave, Silver Spring, MD 20910, USA
    J Infect Dis 200:337-46. 2009
    ..To further increase the efficacy of malaria vaccine RTS,S/AS02A, we tested the RTS,S antigen formulated using the AS01B Adjuvant System (GlaxoSmithKline Biologicals)...
  12. pmc The relationship between anti-merozoite antibodies and incidence of Plasmodium falciparum malaria: A systematic review and meta-analysis
    Freya J I Fowkes
    The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia
    PLoS Med 7:e1000218. 2010
    ..However, published evidence of the protective effect of these antibodies is conflicting...
  13. pmc The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody
    Alexander D Douglas
    Jenner Institute, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford OX3 7DQ, UK
    Nat Commun 2:601. 2011
    ..falciparum is a degenerate process involving a series of parallel redundant pathways...
  14. pmc Advances and challenges in malaria vaccine development
    Peter D Crompton
    Laboratory of Immunogenetics, National Institute of Allergy and Infectious Disease NIAID, NIH, Rockville, Maryland, USA
    J Clin Invest 120:4168-78. 2010
    ..A better understanding of the mechanisms of naturally acquired immunity to malaria may lead to insights for vaccine development...
  15. pmc Prime-boost immunization with adenoviral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses
    Arturo Reyes-Sandoval
    The Jenner Institute, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford OX3 7DQ, United Kingdom
    Infect Immun 78:145-53. 2010
    ....
  16. ncbi Immune effector mechanisms in malaria
    K Marsh
    KEMRI Centre for Geographic Medicine Research Coast CGMRC, PO Box 230, Kilifi, Kenya
    Parasite Immunol 28:51-60. 2006
    ....
  17. ncbi Apical membrane antigen 1: a malaria vaccine candidate in review
    Edmond J Remarque
    Department of Parasitology, Biomedical Primate Research Centre, 2280 GH Rijswijk, The Netherlands
    Trends Parasitol 24:74-84. 2008
    ..The current understanding of AMA1 will be presented, particularly in relation to the vaccine potential of AMA1 and the approaches being taken towards clinical development...
  18. pmc A review of malaria vaccine clinical projects based on the WHO rainbow table
    Lauren Schwartz
    Initiative for Vaccine Research, Department of Immunization, Vaccines and Biologicals, World Health Organization, Avenue Appia 20, 1211 CH 27, Geneva, Switzerland
    Malar J 11:11. 2012
    ..Field trials of several research malaria vaccines have also confirmed that it is possible to impact the host-parasite relationship through vaccine-induced ..
  19. pmc Ensemble modeling of the likely public health impact of a pre-erythrocytic malaria vaccine
    Thomas Smith
    Swiss Tropical and Public Health Institute, Basel, Switzerland
    PLoS Med 9:e1001157. 2012
    ..Their applicability to low transmission settings is unclear. Evaluations of the efficiency of different deployment strategies in diverse settings should consider uncertainties in model structure...
  20. pmc A prospective analysis of the Ab response to Plasmodium falciparum before and after a malaria season by protein microarray
    Peter D Crompton
    Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20852, USA
    Proc Natl Acad Sci U S A 107:6958-63. 2010
    ....
  21. ncbi Erythrocyte and reticulocyte binding-like proteins of Plasmodium falciparum
    Wai Hong Tham
    Walter and Eliza Hall Institute of Medical Research, University of Melbourne, Parkville, Vic, Australia
    Trends Parasitol 28:23-30. 2012
    ....
  22. pmc Vaccines against malaria
    Adrian V S Hill
    The Jenner Institute, University of Oxford, Old Road Campus Research Building, Oxford OX37DQ, UK
    Philos Trans R Soc Lond B Biol Sci 366:2806-14. 2011
    ..The most attractive near-term approach to develop such a product is to combine existing partially effective pre-erythrocytic vaccine candidates...
  23. pmc Efficacy of RTS,S malaria vaccines: individual-participant pooled analysis of phase 2 data
    Philip Bejon
    KEMRI Wellcome Trust Research Programme, Kenya Medical Research Institute, Kilifi, Kenya
    Lancet Infect Dis 13:319-27. 2013
    ..To ascertain variations in vaccine efficacy according to covariates such as transmission intensity, choice of adjuvant, age at vaccination, and bednet use, we did an individual-participant pooled analysis of phase 2 clinical data...
  24. ncbi From the circumsporozoite protein to the RTS, S/AS candidate vaccine
    Joe Cohen
    GlaxoSmithKline Biologicals, Belgium
    Hum Vaccin 6:90-6. 2010
    ....
  25. ncbi The future for blood-stage vaccines against malaria
    Jack S Richards
    Infection and Immunity Division, Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia
    Immunol Cell Biol 87:377-90. 2009
    ..Additionally, objective criteria and approaches are needed to prioritize the large number of candidate antigens, and strong candidates need to be tested in clinical trials as quickly as possible...
  26. ncbi Enhancing blood-stage malaria subunit vaccine immunogenicity in rhesus macaques by combining adenovirus, poxvirus, and protein-in-adjuvant vaccines
    Simon J Draper
    Jenner Institute, University of Oxford, Oxford, OX3 7DQ, United Kingdom
    J Immunol 185:7583-95. 2010
    ..These data encourage the further clinical development and coadministration of protein and viral vector vaccine platforms in an attempt to induce broad cellular and humoral immune responses against blood-stage malaria Ags in humans...
  27. pmc Unexpected fold in the circumsporozoite protein target of malaria vaccines
    Michael B Doud
    Immune Disease Institute, Children s Hospital Boston and Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 109:7817-22. 2012
    ..Elucidation of a unique structure of a domain within CS enables rational design of next-generation subunit vaccines and functional and medicinal chemical investigation of the conserved hydrophobic pocket...
  28. ncbi Experimental human challenge infections can accelerate clinical malaria vaccine development
    Robert W Sauerwein
    Robert W Sauerwein and Meta Roestenberg are at the Department of Medical Microbiology, Radboud University Nijmegen Medical Centre, HB Nijmegen, The Netherlands
    Nat Rev Immunol 11:57-64. 2011
    ..Several candidate malaria vaccines have reached Phase IIb clinical trials, but results have often been disappointing...
  29. ncbi Calculation of liver-to-blood inocula, parasite growth rates, and preerythrocytic vaccine efficacy, from serial quantitative polymerase chain reaction studies of volunteers challenged with malaria sporozoites
    Philip Bejon
    Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Oxford, United Kingdom
    J Infect Dis 191:619-26. 2005
    ..number and growth rate of Plasmodium falciparum parasites emerging in recipients of candidate preerythrocytic malaria vaccines and unvaccinated control subjects undergoing mosquito-bite challenge...
  30. pmc Protective CD8+ T lymphocytes in primates immunized with malaria sporozoites
    Walter R Weiss
    Infectious Disease Department, Naval Medical Research Center, Silver Spring, Maryland, United States of America
    PLoS ONE 7:e31247. 2012
    Live attenuated malaria vaccines are more potent than the recombinant protein, bacterial or viral platform vaccines that have been tested, and an attenuated sporozoite vaccine against falciparum malaria is being developed for humans...
  31. pmc Plasmodium vivax: who cares?
    Mary R Galinski
    Emory Vaccine Center and Yerkes National Primate Research Center, Division of Infectious Diseases, Department of Medicine, School of Medicine, Emory University, Atlanta, GA, USA
    Malar J 7:S9. 2008
    ....
  32. pmc Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A
    Michele D Spring
    United States Military Malaria Vaccine Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America
    PLoS ONE 4:e5254. 2009
    ....
  33. ncbi The RTS,S malaria vaccine
    Sofia Casares
    US Military Malaria Vaccine Program, Naval Medical Research Center Walter Reed Army Institute of Research, Silver Spring, MD, USA
    Vaccine 28:4880-94. 2010
    ..This review will focus on current knowledge about the protective efficacy of RTS,S and what we have learned regarding its impact on the human immune system...
  34. pmc An inhibitory antibody blocks interactions between components of the malarial invasion machinery
    Christine R Collins
    Division of Parasitology, National Institute for Medical Research, Mill Hill, London, United Kingdom
    PLoS Pathog 5:e1000273. 2009
    ..We propose that mAb 4G2 inhibits invasion by preventing PfAMA1 from interacting with other components of the invasion complex. Our findings should aid the rational design of subunit malaria vaccines based on PfAMA1.
  35. pmc Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara
    Daniel P Webster
    Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Churchill Hospital, Old Road, Oxford OX3 7LJ, UK
    Proc Natl Acad Sci U S A 102:4836-41. 2005
    ....
  36. ncbi Long-term safety and efficacy of the RTS,S/AS02A malaria vaccine in Mozambican children
    Jahit Sacarlal
    Centro de Investigação em Saúde de Manhiça CISM Manhiça, Mozambique
    J Infect Dis 200:329-36. 2009
    ..We previously reported that the RTS,S/AS02A vaccine had an acceptable safety profile, was immunogenic, and demonstrated efficacy against Plasmodium falciparum malaria disease for 21 months...
  37. pmc Immunological mechanisms underlying protection mediated by RTS,S: a review of the available data
    Vasee S Moorthy
    Initiative for Vaccine Research, World Health Organization, 1211 Geneva 27, Switzerland
    Malar J 8:312. 2009
    ..In this article, what is known about mechanisms involved in partial protection against malaria induced by RTS,S is reviewed...
  38. ncbi A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea
    Blaise Genton
    Papua New Guinea Institute of Medical Research, Maprik, Papua New Guinea
    J Infect Dis 185:820-7. 2002
    ..The vaccine-induced selection pressure exerted on the parasites and its consequences for morbidity strongly argue for developing vaccines comprising conserved antigens and/or multiple components covering all important allelic types...
  39. ncbi Reticulocyte-binding protein homologue 5 - an essential adhesin involved in invasion of human erythrocytes by Plasmodium falciparum
    Jake Baum
    Division of Infection and Immunity, The Walter and Eliza Hall Institute of Medical Research, Vic, Australia
    Int J Parasitol 39:371-80. 2009
    ..Given its small size, we believe PfRh5 may prove to be a valuable candidate for inclusion in a multi-component anti-malarial vaccine...
  40. pmc Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51
    Yimin Wu
    Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, Rockville, Maryland, United States of America
    PLoS ONE 3:e2636. 2008
    ..This single blinded, dose escalating, controlled Phase 1 study assessed the safety and immunogenicity of recombinant Pfs25 and Pvs25 formulated with Montanide ISA 51, a water-in-oil emulsion...
  41. ncbi Towards a comprehensive simulation model of malaria epidemiology and control
    T Smith
    Swiss Tropical Institute, Socinstrasse 57, PO Box, CH 4002 Basel, Switzerland
    Parasitology 135:1507-16. 2008
    ..The project thus provides a general platform for comparing, fitting, and evaluating different model structures, and for quantitative prediction of effects of different interventions and integrated control programmes...
  42. ncbi The circumsporozoite protein is an immunodominant protective antigen in irradiated sporozoites
    Kota Arun Kumar
    Michael Heidelberger Division of Immunology, Department of Pathology, New York University School of Medicine, New York, New York 10016, USA
    Nature 444:937-40. 2006
    ..Thus, although hundreds of other Plasmodium genes are expressed in sporozoites and EEFs, CS is a dominant protective antigen. Nevertheless, sterile immunity could be obtained by immunization of CS transgenics with three doses of IrSp...
  43. ncbi A consultation on the optimization of controlled human malaria infection by mosquito bite for evaluation of candidate malaria vaccines
    Matthew B Laurens
    Howard Hughes Medical Institute Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD, United States
    Vaccine 30:5302-4. 2012
    Early clinical investigations of candidate malaria vaccines and antimalarial medications increasingly employ an established model of controlled human malaria infection (CHMI)...
  44. ncbi CD8+ T effector memory cells protect against liver-stage malaria
    Arturo Reyes-Sandoval
    The Jenner Institute, University of Oxford, Oxford OX3 7DQ, United Kingdom
    J Immunol 187:1347-57. 2011
    ..Thus, we identify persistent CD8 T(EM) populations as essential for vaccine-induced pre-erythrocytic protection against malaria, a finding that has important implications for vaccine design...
  45. ncbi Efficacy of preerythrocytic and blood-stage malaria vaccines can be assessed in small sporozoite challenge trials in human volunteers
    Meta Roestenberg
    Department of Medical Microbiology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands
    J Infect Dis 206:319-23. 2012
    ..Sporozoite challenge trials are thus a powerful tool for early selection of candidates that warrant efficacy of trials in the field...
  46. pmc The biology of sexual development of Plasmodium: the design and implementation of transmission-blocking strategies
    Robert E Sinden
    The Jenner Institute, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford OX3 7DQ, UK
    Malar J 11:70. 2012
    ....
  47. ncbi Whole parasite vaccination approaches for prevention of malaria infection
    Noah S Butler
    Department of Microbiology, University of Iowa, Iowa City, IA, USA
    Trends Immunol 33:247-54. 2012
    ....
  48. pmc Pre-erythrocytic malaria vaccines: identifying the targets
    Patrick E Duffy
    Laboratory of Malaria Immunology and Vaccinology, Division of Intramural Research, NIAID, NIH, Rockville, MD, USA
    Expert Rev Vaccines 11:1261-80. 2012
    Pre-erythrocytic malaria vaccines target Plasmodium during its sporozoite and liver stages, and can prevent progression to blood-stage disease, which causes a million deaths each year...
  49. ncbi Human antibodies to recombinant protein constructs of Plasmodium falciparum Apical Membrane Antigen 1 (AMA1) and their associations with protection from malaria
    Spencer D Polley
    Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK
    Vaccine 23:718-28. 2004
    ..Results encourage the development of an AMA1 vaccine based on the full-length ectodomain, and indicate that the function of human antibodies to allele-specific and conserved epitopes in AMA1 should be studied further...
  50. pmc Adenovirus-5-vectored P. falciparum vaccine expressing CSP and AMA1. Part B: safety, immunogenicity and protective efficacy of the CSP component
    Cindy Tamminga
    U S Military Malaria Vaccine Program, Naval Medical Research Center, Silver Spring, Maryland, United States of America
    PLoS ONE 6:e25868. 2011
    ..As adenovirus vaccine vectors induce both these responses in humans, a Phase 1/2a clinical trial was conducted to evaluate the efficacy of an adenovirus serotype 5-vectored malaria vaccine against sporozoite challenge...
  51. pmc Reticulocyte and erythrocyte binding-like proteins function cooperatively in invasion of human erythrocytes by malaria parasites
    Sash Lopaticki
    The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3050, Australia
    Infect Immun 79:1107-17. 2011
    ..This validates the use of a combination of these ligands as a potential vaccine that would have broad activity against P. falciparum...
  52. pmc Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age
    Philip Bejon
    Centre for Geographic Medicine Research Coast, Kenya Medical Research Institute, Kilifi, Kenya
    N Engl J Med 359:2521-32. 2008
    ..We evaluated the efficacy of RTS,S given with a more immunogenic adjuvant system (AS01E) in children 5 to 17 months of age, a target population for vaccine licensure...
  53. pmc Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5-17 months in Kenya and Tanzania: a randomised controlled trial
    Ally Olotu
    Kenya Medical Research Institute Wellcome Trust Programme, Centre for Geographic Medicine Research, Kenya Medical Research Institute, Kilifi, Kenya
    Lancet Infect Dis 11:102-9. 2011
    ..We recently showed efficacy against clinical falciparum malaria in 5-17 month old children, during an average of 8 months follow-up. We aimed to assess the efficacy of RTS,S/AS01E during 15 months of follow-up...
  54. pmc Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Alhydrogel, Montanide ISA 720 or AS02
    Meta Roestenberg
    Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    PLoS ONE 3:e3960. 2008
    ..Plasmodium falciparum Apical Membrane Antigen 1 (PfAMA1) is a candidate vaccine antigen expressed by merozoites and sporozoites. It plays a key role in red blood cell and hepatocyte invasion that can be blocked by antibodies...
  55. ncbi Adenovectors induce functional antibodies capable of potent inhibition of blood stage malaria parasite growth
    Joseph T Bruder
    GenVec, Inc, 65 West Watkins Mill Road, Gaithersburg, MD 20878, USA
    Vaccine 28:3201-10. 2010
    ..These data highlight the importance of rational vaccine design and support the advancement of adenovector delivery technology for a malaria vaccine...
  56. pmc Generation of humoral immune responses to multi-allele PfAMA1 vaccines; effect of adjuvant and number of component alleles on the breadth of response
    Kwadwo A Kusi
    Department of Parasitology, Biomedical Primate Research Centre, Rijswijk, The Netherlands
    PLoS ONE 5:e15391. 2010
    ..Our data confirms the feasibility and potential of multi-allele PfAMA1 formulations, and highlights the need for adjuvants with improved antibody potentiation properties for AMA1-based vaccines...
  57. ncbi Malaria vaccine design: immunological considerations
    Michael F Good
    Division of Immunology, The Queensland Institute of Medical Research, Brisbane, QLD 4006, Australia
    Immunity 33:555-66. 2010
    ..These and other concepts will be discussed in this review...
  58. ncbi Effective induction of high-titer antibodies by viral vector vaccines
    Simon J Draper
    The Jenner Institute, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Headington, Oxford OX3 7DQ, UK
    Nat Med 14:819-21. 2008
    ..Antibodies induced against a blood-stage malaria antigen by this viral vector platform are highly effective against Plasmodium yoelii parasites in mice and against Plasmodium falciparum in vitro...
  59. ncbi Quantitative real-time polymerase chain reaction for malaria diagnosis and its use in malaria vaccine clinical trials
    Laura Andrews
    Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK
    Am J Trop Med Hyg 73:191-8. 2005
    ..This PCR method has so far been used to follow 137 vaccinee and control volunteers in Phase IIa trials in Oxford and on 220 volunteer samples during a Phase IIb field trial in The Gambia...
  60. ncbi Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria
    Stephen L Hoffman
    Sanaria Inc, Rockville, MD, USA
    Hum Vaccin 6:97-106. 2010
    ..A medium term goal is to design and build a facility for manufacturing highly potent and stable vaccine for pivotal Phase 3 studies and commercial launch...
  61. ncbi Testing vaccines in human experimental malaria: statistical analysis of parasitemia measured by a quantitative real-time polymerase chain reaction
    Cornelus C Hermsen
    Department of Medical Microbiology, University Medical Center, Nijmegen, The Netherlands
    Am J Trop Med Hyg 71:196-201. 2004
    Clinical trials are an essential step in evaluation of safety and efficacy of malaria vaccines, and human experimental malaria infections have been used for evaluation of protective immunity of Plasmodium falciparum malaria...
  62. pmc Protective CD8 T cells against Plasmodium liver stages: immunobiology of an 'unnatural' immune response
    Michael Glen Overstreet
    Molecular Microbiology and Immunology, Johns Hopkins University, Bloomberg School of Public Health, Baltimore, MD 21205, USA
    Immunol Rev 225:272-83. 2008
    ..Finally, we discuss the impact of the immunodominant CS protein on this protection and the implications of these findings for vaccine design...
  63. ncbi Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial
    Kwaku Poku Asante
    Kintampo Health Research Centre, Kintampo, Ghana
    Lancet Infect Dis 11:741-9. 2011
    ..8 month follow-up data have been reported for safety and immunogenicity of RTS,S/AS01(E) when integrated into the EPI. We report extended follow-up to 19 months, including efficacy results...
  64. pmc Adenovirus 5-vectored P. falciparum vaccine expressing CSP and AMA1. Part A: safety and immunogenicity in seronegative adults
    Martha Sedegah
    U S Military Malaria Vaccine Program, Naval Medical Research Center, Silver Spring, Maryland, United States of America
    PLoS ONE 6:e24586. 2011
    ....
  65. ncbi Widespread functional specialization of Plasmodium falciparum erythrocyte membrane protein 1 family members to bind CD36 analysed across a parasite genome
    Bridget A Robinson
    Department of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, CO 80525, USA
    Mol Microbiol 47:1265-78. 2003
    ..These can be used to investigate the role of proteins in malaria pathogenesis and potentially tailor vaccines to recognize particular binding variants...
  66. pmc Immunization with VAR2CSA-DBL5 recombinant protein elicits broadly cross-reactive antibodies to placental Plasmodium falciparum-infected erythrocytes
    Marion Avril
    Seattle Biomedical Research Institute, 307 Westlake Ave N, Suite 500, Seattle, WA 98109 5219, USA
    Infect Immun 78:2248-56. 2010
    ..These findings demonstrate that the major PfEMP1 variant expressed by placental isolates exposes strain-transcendent epitopes that can be targeted by vaccination and may have application for pregnancy malaria vaccine development...
  67. pmc High antibody titer against apical membrane antigen-1 is required to protect against malaria in the Aotus model
    Sheetij Dutta
    Department of Epitope Mapping, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America
    PLoS ONE 4:e8138. 2009
    ..High titers of cross-strain inhibitory antibodies against AMA1 are therefore critical to confer solid protection, and the Aotus model can be used to down-select future AMA1 formulations, prior to advanced human trials...
  68. pmc A randomized controlled phase 2 trial of the blood stage AMA1-C1/Alhydrogel malaria vaccine in children in Mali
    Issaka Sagara
    Malaria Research and Training Center, Faculty of Medicine Pharmacy and Dentistry BP 1805 Bamako, University of Bamako, Mali, Malaysia
    Vaccine 27:3090-8. 2009
    ..5 g/dL, in the direction of lower hemoglobin in the children who received AMA1-C1, although these differences were not significant after correction for multiple tests. These differences were not seen in the second year of transmission...
  69. ncbi The development of the RTS,S malaria vaccine candidate: challenges and lessons
    W R Ballou
    Infectious Diseases Development, Global Health Division, Bill and Melinda Gates Foundation, PO Box 23350, Seattle, WA, USA
    Parasite Immunol 31:492-500. 2009
    ....
  70. pmc DNA prime/Adenovirus boost malaria vaccine encoding P. falciparum CSP and AMA1 induces sterile protection associated with cell-mediated immunity
    Ilin Chuang
    US Military Malaria Vaccine Program, Naval Medical Research Center, Silver Spring, Maryland, United States of America
    PLoS ONE 8:e55571. 2013
    ..We tested a DNA prime/adenovirus boost malaria vaccine in a Phase 1 clinical trial with controlled human malaria infection...
  71. ncbi Antibodies to the conserved C-terminal domain of the Plasmodium falciparum merozoite surface protein 1 and to the merozoite extract and their relationship with in vitro inhibitory antibodies and protection against clinical malaria in a Senegalese village
    Ronald Perraut
    Unite d immunologie, Institut Pasteur de Dakar, 36 Ave Pasteur, BP 220, Dakar, Senegal
    J Infect Dis 191:264-71. 2005
    ..High levels of anti-PfMSP-1p19 immunoglobulin G were associated with reduced malaria in an age-adjusted multivariate analysis. These results support baculovirus PfMSP-1p19-based vaccine development...
  72. ncbi Protective T cell immunity against malaria liver stage after vaccination with live sporozoites under chloroquine treatment
    Elodie Belnoue
    Department of Immunology, Institut National de la Sante et de la Recherche Medicale, Unité 567, Centre National de la Recherche Scientifique, Universite Rene Descartes, Hopital Cochin, Paris, France
    J Immunol 172:2487-95. 2004
    ..CD4(+) and CD8(+) T cells were, however, responsible for the protection through the induction of IFN-gamma and NO...
  73. ncbi Immune responses against a liver-stage malaria antigen induced by simian adenoviral vector AdCh63 and MVA prime-boost immunisation in non-human primates
    Stefania Capone
    Okairos, via dei Castelli Romani 22, 00040 Pomezia, Rome, Italy
    Vaccine 29:256-65. 2010
    ..These results in non-human primates highlight the potential of this vaccination regime and encourage its future use in clinical trials...
  74. pmc Blood stage vaccines for Plasmodium falciparum: current status and the way forward
    Ruth D Ellis
    Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, USA
    Hum Vaccin 6:627-34. 2010
    ..Alternative preclinical and clinical development paths will speed iterative development...
  75. pmc Circumsporozoite-specific T cell responses in children vaccinated with RTS,S/AS01E and protection against P falciparum clinical malaria
    Ally Olotu
    Kenya Medical Research Institute Wellcome Trust Programme, Centre for Geographic Medicine Research, Coast, Kilifi, Kenya
    PLoS ONE 6:e25786. 2011
    ..falciparum. We studied CS-specific T cell responses in order to identify correlates of protection...
  76. ncbi Single-dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei
    Arturo Reyes-Sandoval
    The Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK
    Eur J Immunol 38:732-41. 2008
    ..Our data suggest that T(EM) cells are important as a first line of defense against fast-replicating pathogens such as murine Plasmodium and demonstrate the potential of replication-defective SAd as future malaria vaccines for humans.
  77. pmc Measuring naturally acquired immune responses to candidate malaria vaccine antigens in Ghanaian adults
    Daniel Dodoo
    Noguchi Memorial Institute for Medical Research, University of Ghana, Legon, Ghana
    Malar J 10:168. 2011
    ..Assessing T cell responses is especially challenging, given genetic restriction, low responses observed in endemic areas, their variability over time, potential suppression by parasitaemia and the intrinsic variability of the assays...
  78. ncbi Blood-stage malaria vaccines - recent progress and future challenges
    A L Goodman
    The Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK
    Ann Trop Med Parasitol 104:189-211. 2010
    ..The future challenges that face this field of vaccine research are also described...
  79. ncbi High efficacy of anti DBL4ɛ-VAR2CSA antibodies in inhibition of CSA-binding Plasmodium falciparum-infected erythrocytes from pregnant women
    Pamela A Magistrado
    Centre for Medical Parasitology, Department of International Health, Immunology and Microbiology, University of Copenhagen, Denmark
    Vaccine 29:437-43. 2011
    ..The most promising recombinant protein elicited antibodies with similar efficacy as pooled plasma from immune multi-gravid African women...
  80. pmc Development and characterization of a standardized ELISA including a reference serum on each plate to detect antibodies induced by experimental malaria vaccines
    Kazutoyo Miura
    Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA
    Vaccine 26:193-200. 2008
    ..Since this ELISA method gives reliable antibody titer with less labor than other methods, it can strongly support vaccine development...
  81. pmc A diversity-covering approach to immunization with Plasmodium falciparum apical membrane antigen 1 induces broader allelic recognition and growth inhibition responses in rabbits
    Edmond J Remarque
    Department of Parasitology, Biomedical Primate Research Centre, Lange Kleiweg 139, 2288 GJ Rijswijk, The Netherlands
    Infect Immun 76:2660-70. 2008
    ..This suggests that vaccines based upon the DiCo mix approach provide a broader functional immunity than immunization with a single allele...
  82. pmc Induction of adhesion-inhibitory antibodies against placental Plasmodium falciparum parasites by using single domains of VAR2CSA
    Morten A Nielsen
    Department of International Health, Immunology, and Microbiology, University of Copenhagen, Department of Infectious Diseases, Copenhagen University Hospital, Copenhagen, Denmark
    Infect Immun 77:2482-7. 2009
    ..As the inhibition was not limited to homologous parasite strains, it seems feasible to base a protective malaria vaccine on a single VAR2CSA DBL domain...
  83. pmc Effect of the pre-erythrocytic candidate malaria vaccine RTS,S/AS01E on blood stage immunity in young children
    Philip Bejon
    Kenya Medical Research Institute, Centre for Geographic Medicine Research, Kilifi, Kenya
    J Infect Dis 204:9-18. 2011
    ..RTS,S/AS01(E) is the lead candidate malaria vaccine and confers pre-erythrocytic immunity. Vaccination may therefore impact acquired immunity to blood-stage malaria parasites after natural infection...
  84. ncbi Production, quality control, stability and pharmacotoxicity of cGMP-produced Plasmodium falciparum AMA1 FVO strain ectodomain expressed in Pichia pastoris
    Bart W Faber
    Department of Parasitology, Biomedical Primate Research Center, Lange Kleiweg 139, 2288 GJ Rijswijk, The Netherlands
    Vaccine 26:6143-50. 2008
    ..These formulations also showed no pharmacotoxicity in rabbits. The final product conformed to preset criteria and was judged suitable for use in human clinical trials...
  85. pmc Extreme CD8 T cell requirements for anti-malarial liver-stage immunity following immunization with radiation attenuated sporozoites
    Nathan W Schmidt
    Department of Microbiology, University of Iowa, Iowa City, Iowa, United States of America
    PLoS Pathog 6:e1000998. 2010
    ..These data provide new insights into protective CD8 T cell responses elicited by RAS-immunization in genetically diverse hosts, information with relevance to developing attenuated whole-parasite vaccines...
  86. pmc Evidence for erythrocyte-binding antigen 175 as a component of a ligand-blocking blood-stage malaria vaccine
    Lubin Jiang
    Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA
    Proc Natl Acad Sci U S A 108:7553-8. 2011
    ..Our findings suggest that antibodies to region II of EBA-175, as one component of a ligand-blocking malaria vaccine, are largely unaffected by polymorphism in EBA-175...
  87. pmc Superior antimalarial immunity after vaccination with late liver stage-arresting genetically attenuated parasites
    Noah S Butler
    Department of Microbiology, University of Iowa, 3 512 Bowen Science Building, Iowa City, IA 52242, USA
    Cell Host Microbe 9:451-62. 2011
    ..the potential utility of late liver stage-arresting GAP as broadly protective next-generation live-attenuated malaria vaccines and support their potential as a powerful model for identifying antigens to generate cross-stage protection.
  88. pmc Safety and immunogenicity of a recombinant nonglycosylated erythrocyte binding antigen 175 Region II malaria vaccine in healthy adults living in an area where malaria is not endemic
    H M El Sahly
    Departments of Molecular Virology and Microbiology and Medicine, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
    Clin Vaccine Immunol 17:1552-9. 2010
    ..falciparum at low levels compared to sera from placebo recipients or preimmune sera. In conclusion, the EBA-175 vaccine with adjuvant was safe and immunogenic in malaria-naïve subjects...
  89. ncbi Mathematical modeling of the impact of malaria vaccines on the clinical epidemiology and natural history of Plasmodium falciparum malaria: Overview
    Thomas Smith
    Swiss Tropical Institute, Basel, Switzerland
    Am J Trop Med Hyg 75:1-10. 2006
    ..project to develop integrated mathematical models for predicting the epidemiologic and economic effects of malaria vaccines both at the individual and population level...
  90. pmc The quantity and quality of African children's IgG responses to merozoite surface antigens reflect protection against Plasmodium falciparum malaria
    David Courtin
    Medical Microbiology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    PLoS ONE 4:e7590. 2009
    ..Evaluating such responses in longitudinal sero-epidemiological field studies, allied to increasing knowledge of the immunological mechanisms associated with anti-malarial protection, will help in the development of malaria vaccines.
  91. ncbi Safety and immunogenicity of GMZ2 - a MSP3-GLURP fusion protein malaria vaccine candidate
    Meral Esen
    University of Tubingen, Institute of Tropical Medicine, Wilhelmstrasse 27, D 72074 Tubingen, Germany
    Vaccine 27:6862-8. 2009
    ..We conclude that GMZ2 is a safe and immunogenic malaria vaccine candidate suitable for further clinical development...
  92. ncbi Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria
    C F Ockenhouse
    Department of Immunology, Walter Reed Army Institute of Research, Washington, DC 20307, USA
    J Infect Dis 177:1664-73. 1998
    Candidate malaria vaccines have failed to elicit consistently protective immune responses against challenge with Plasmodium falciparum. NYVAC-Pf7, a highly attenuated vaccinia virus with 7 P...
  93. pmc Several domains from VAR2CSA can induce Plasmodium falciparum adhesion-blocking antibodies
    Ali Salanti
    Centre for Medical Parasitology at Department of International Health, Immunology and Microbiology, University of Copenhagen and Department of Infectious Diseases, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark
    Malar J 9:11. 2010
    ..It has previously been shown that one domain of VAR2CSA, DBL4-FCR3, induces parasite adhesion-blocking antibodies. In this study, it is demonstrated that other domains of VAR2CSA also can induce antibodies with inhibitory activity...
  94. pmc Flipping the paradigm on malaria transmission-blocking vaccines
    Rhoel R Dinglasan
    Johns Hopkins Malaria Research Institute, Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA
    Trends Parasitol 24:364-70. 2008
    ..Here, we review the current state of knowledge of mosquito-based TBVs and discuss the utility of this approach for future vaccine development...
  95. ncbi Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans
    Samuel J McConkey
    Nuffield Department of Medicine, University of Oxford, John Radcliffe Hospital, Oxford, OX3 9DU, UK
    Nat Med 9:729-35. 2003
    ..Such heterologous prime-boost immunization approaches may provide a basis for preventative and therapeutic vaccination in humans...
  96. ncbi The complexity of protective immunity against liver-stage malaria
    D L Doolan
    Malaria Program, Naval Medical Research Center, Silver Spring, MD 20910, USA
    J Immunol 165:1453-62. 2000
    ....
  97. ncbi Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime-boost immunisation regimes
    Sarah C Gilbert
    Wellcome Trust Centre for Human Genetics, University of Oxford, Roosevelt Drive, OX3 7BN, Oxford, UK
    Vaccine 20:1039-45. 2002
    ..This study identifies recombinant replication-defective adenovirus as an alternative to recombinant replication-defective poxviruses as boosting agents for the induction of strong protective CD8(+) T cell responses...
  98. ncbi VAR2CSA is the principal ligand for chondroitin sulfate A in two allogeneic isolates of Plasmodium falciparum
    Michael F Duffy
    The Department of Medicine, The University of Melbourne, The Royal Melbourne Hospital, Parkville, VIC 3050, Australia
    Mol Biochem Parasitol 148:117-24. 2006
    ....
  99. ncbi Durable human memory T cells quantifiable by cultured enzyme-linked immunospot assays are induced by heterologous prime boost immunization and correlate with protection against malaria
    Sheila M Keating
    Centre for Clinical Vaccinology and Tropical Medicine, Nuffield Department of Medicine, Churchill Hospital, Oxford, United Kingdom
    J Immunol 175:5675-80. 2005
    ..This cultured assay identifies long-lasting protective T cell responses and therefore offers an attractive option for assessments of vaccine immunogenicity...
  100. ncbi Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara
    J Schneider
    Institute of Molecular Medicine, Nuffield Department of Medicine, University of Oxford, John Radcliffe Hospital, UK
    Nat Med 4:397-402. 1998
    ..DNA priming followed by MVA boosting may provide a general immunization regime for induction of high levels of CD8+ T cells...
  101. pmc Community perceptions of malaria and vaccines in the South Coast and Busia regions of Kenya
    David I Ojakaa
    African Medical and Research Foundation, Wilson Airport, Langata Road, PO Box 30125, Nairobi, Kenya
    Malar J 10:147. 2011
    ....

Research Grants64

  1. Novel Linear Peptide Universal Malaria Vaccines
    Alberto Moreno; Fiscal Year: 2005
    ..We now aim to investigate further the in vivo relevance of this approach for the design of subunit malaria vaccines. New peptide constructs will be designed containing other promiscuous T cell epitopes, selected from those we ..
  2. Vaccine Development for Falciparum Malaria in Pregnant Women and Their Offspring
    Ian C Michelow; Fiscal Year: 2013
    ..and his team of highly accomplished investigators are committed to the mission of developing new effective malaria vaccines using creative strategies...
  3. Malaria vaccines modified with TLR agonist adjuvant
    Elizabeth H Nardin; Fiscal Year: 2010
    PROJECT SUMMARY/ABSTRACT The potential efficacy of malaria vaccines have been demonstrated experimentally in humans immunized with irradiated sporozoites and in naturally infected individuals living in malaria endemic areas...
  4. Plasmodium vivax recombinant CS protein vaccine for malaria
    B Kim Lee Sim; Fiscal Year: 2012
    ..Malaria cannot be eradicated without eliminating Pv. The only subunit malaria vaccines that have been reproducibly shown to prevent Pf malaria in humans are based on the Pf circumsporozoite ..
  5. Investigation of the characteristics and persistence of memory B cells following
    Jiraprapa Wipasa; Fiscal Year: 2012
    ..provided by applicant): The fact that people can be repeatedly infected with malaria, and that prototype malaria vaccines have not conferred long-term protection, raises the possibility that immunological memory after malaria ..
  6. Oral Immunization Against Malaria with Recombinant Adenoviruses
    GARY W KETNER; Fiscal Year: 2010
    ..These studies will address the feasibility and efficacy of enteric immunization with live adenovirus recombinants and will provide information essential in considering clinical trials of oral recombinant malaria vaccines.
  7. Proteome-wide cellular immunity approach to P. falciparum antigen identification
    ALESSANDRO D SETTE; Fiscal Year: 2012
    ..antigens, and will therefore provide valuable information regarding the potential multivalency of candidate malaria vaccines. It is expected that the proposed research will have important outcomes for malaria vaccine development...
  8. Novel Engineering of a P. falciparum Merozoite Surface Protein 1 Malaria Vaccine
    GEORGE S HUI; Fiscal Year: 2010
    ..The strategy will rapidly lead to a new generation of MSP1-based malaria vaccines deployable with significantly improved efficacy and logistical feasibility, while utilizing the already ..
  9. Memory CD8 T cell immunity to Plasmodium liver stage infec
    John T Harty; Fiscal Year: 2013
    ..However, despite the more than 40 years of research in malaria vaccines, we still know very little about the specific immune mechanisms required for sterilizing immunity to ..
  10. Evolution of Plasmodium vivax and Asian Macaque Malarias
    ANANIAS ALBERTO ESCALANTE; Fiscal Year: 2011
    ..This is a critical step in the parasite life cycle. Several of these proteins are considered targets for malaria vaccines. Spurious evidence of positive selection, however, could result from demographic processes (such as ..
  11. RBL Binding Domain Malaria Candidate Vaccines
    Mary R Galinski; Fiscal Year: 2012
    ..We will learn whether RBL-based malaria vaccines can provide protection against erythrocytic challenge and also develop valuable tools for advancing ..
  12. Universal Attenuated Sporozoite Vaccine and Challenge System
    STEPHEN LEV HOFFMAN; Fiscal Year: 2013
    ..This work was done to facilitate the testing of malaria vaccines against challenge with multiple strains of Pf, and to create the parasite components of a multi-strain PfSPZ ..
  13. Genetic diversity and protective immunity to malaria infection and disease
    Christopher V Plowe; Fiscal Year: 2013
    ..malaria infection and disease, and to use this knowledge to inform the development of broadly protective malaria vaccines. We will exploit recent technological advances to address at the genome-wide level questions that could ..
  14. CD1d/NKT-binding Glycolipids as an Adjuvant for a T cell-based Malaria Vaccine
    Moriya Tsuji; Fiscal Year: 2009
    ..cell ligand, a-galactosylceramide (a-GalCer), can enhance protective CD8+ T cell responses elicited by murine malaria vaccines, including a recombinant adenovirus expressing a malarial antigen...
  15. Pre-erythrocytic Stage Antigen Discovery for Malaria Vaccine Development
    Douglas E Brough; Fiscal Year: 2013
    ..in rodents, non-human primates and humans indicate the existence of protective antigens in whole organism malaria vaccines that induce T cells which target the pre-erythrocytic stages of the malaria parasite...
  16. A protective role for IL-17 in blood-stage malaria
    Jason S Stumhofer; Fiscal Year: 2013
    ....
  17. Immune Profile and Network Analysis of Malaria Infection and Vaccination
    Ruobing Wang; Fiscal Year: 2013
    ..The overall goal of this project is to elucidate the mechanisms of immune protection to malaria in order to accelerate development of a broadly effective malaria vaccine and to advance the process of vaccine development in general. ..
  18. Immunological memory to malaria liver stage antigens
    James Kazura; Fiscal Year: 2006
    ..The studies are relevant to the development of malaria vaccines because these immunogens will ultimately be evaluated in persons with active or previous infection and ..
  19. ANOPHELES VECTOR POTENTIAL FOR MALARIA TRANSMISSION
    John Beier; Fiscal Year: 1991
    ..By focusing on regulatory mechanisms for vector potential, this project will yield new information for studying natural malaria transmission, for evaluating malaria control programs, and for developing and field testing malaria vaccines.
  20. MALARIA VACCINES: CLINICAL RESEARCH AND TRIAL SITES IN ENDEMIC AREAS
    Kwadwo Koram; Fiscal Year: 2010
    ..clinical research capacity on malaria at field sites in Africa to conduct clinical trials of candidate malaria vaccines or other potential malaria prevention and intervention strategies...
  21. MALARIA VACCINES: CLINICAL RESEARCH AND TRIAL SITES IN ENDEMIC AREAS
    Kwadwo Koram; Fiscal Year: 2011
    ..clinical research capacity on malaria at field sites in Africa to conduct clinical trials of candidate malaria vaccines or other potential malaria prevention and intervention strategies...
  22. MALARIA VACCINES: CLINICAL RESEARCH AND TRIAL SITES IN ENDEMIC AREAS
    Kwadwo Koram; Fiscal Year: 2009
    ..clinical research capacity on malaria at field sites in Africa to conduct clinical trials of candidate malaria vaccines or other potential malaria prevention and intervention strategies...
  23. The Statistical and Computational Analysis of Flow Cytometry Data
    Raphael Gottardo; Fiscal Year: 2013
    ..to a number of different scenarios such as the identification of immune correlate of protections for HIV and malaria vaccines, the identification of genetic mechanisms of homeostasis, and the clinical prediction of chronic inflammatory ..
  24. GENE EXPRESSION AND REGULATION IN P. FALCIPARUM
    DAVID BZIK; Fiscal Year: 1992
    ..falciparum, mosquito insecticide resistance and possible failure or slow development f malaria vaccines has stimulated the need to identify alternative strategies to combat malaria...
  25. MALARIA VACCINE--ATTENUATED INFLUENZA & VACCINIA VECTORS
    Ruth Nussenzweig; Fiscal Year: 2001
    ..With the purpose of developing safe and effective malaria vaccines, she will generate highly attenuated recombinant viruses expressing an optimal set of CS epitopes...
  26. Plasmodium Sporozoites Motility and Cell Invasion
    Dyann Wirth; Fiscal Year: 2006
    ..Identification of TRAP-interacting molecules in the parasite or the host cell will further our understanding of sporozoite motility and invasion and will provide the basis for developing new malaria vaccines and chemotherapeutic agents.
  27. MALARIA VACCINE PRODUCTION AND SUPPORT SERVICES
    KATHLEEN KOOTZ; Fiscal Year: 2012
    ..and development services supporting process development and pilot plot production of promising candidate malaria vaccines into well-characterized malaria vaccine products suitable for evaluation in clinical studies...
  28. MALARIA VACCINE PRODUCTION AND SUPPORT SERVICES
    KATHLEEN KOOTZ; Fiscal Year: 2009
    ..and development services supporting process development and pilot plot production of promising candidate malaria vaccines into well-characterized malaria vaccine products suitable for evaluation in clinical studies...
  29. MALARIA VACCINE PRODUCTION AND SUPPORT SERVICES
    KATHLEEN KOOTZ; Fiscal Year: 2010
    ..and development services supporting process development and pilot plot production of promising candidate malaria vaccines into well-characterized malaria vaccine products suitable for evaluation in clinical studies...
  30. MALARIA VACCINE PRODUCTION AND SUPPORT SERVICES
    KATHLEEN KOOTZ; Fiscal Year: 2013
    ..and development services supporting process development and pilot plot production of promising candidate malaria vaccines into well-characterized malaria vaccine products suitable for evaluation in clinical studies...
  31. MALARIA VACCINE PRODUCTION AND SUPPORT SERVICES
    KATHLEEN KOOTZ; Fiscal Year: 2011
    ..and development services supporting process development and pilot plot production of promising candidate malaria vaccines into well-characterized malaria vaccine products suitable for evaluation in clinical studies...
  32. Modulation of Immunity to Malaria by Nematode Infection
    Mary Stevenson; Fiscal Year: 2004
    ..One of the factors responsible for the disappointing results of recent human trials with recombinant subunit malaria vaccines has recently been suggested to be concurrent helminth infection...
  33. MEMBRANE TRAFFICKING IN MALARIA INFECTED ERYTHROCYTES
    THEODORE TARASCHI; Fiscal Year: 1991
    ..With the evolution of chloroquine-resistant strains of P. falciparum and efficacious malaria vaccines still many years away, new strategies based on recent developments in the biochemistry of malarial parasites ..
  34. Immunogenicity of Synthetic Peptide Malaria Vaccines
    Elizabeth Nardin; Fiscal Year: 2009
    ..abstract_text> ..
  35. MALARIA AND IMMUNE RESPONSES OF CORD BLOOD CELLS
    Urszula Krzych; Fiscal Year: 2000
    ..Understanding of these early responses is essential for future studies seeking to elucidate mechanisms underlying age-related protective immunity, a pivotal point in the development of malaria vaccines.
  36. T Cell Memory and Protection Against Placental Malaria
    Julie Moore; Fiscal Year: 2005
    ..in the immunomodulated state of pregnancy will facilitate application of immunologic tools, such as malaria vaccines when they become available, to the prevention and control of malaria in pregnant women...
  37. DEVELOPMENT OF RECOMBINANT BCG VACCINES FOR MALARIA
    CAROL BERKOWER; Fiscal Year: 2001
    ..yoelii sporozoites. The immunization studies will test the ability of rBCG/malaria vaccines to stimulate an immune response against the P...
  38. RECOMBINANT BCG MALARIA VACCINES
    William Jacobs; Fiscal Year: 2001
    ..The immunization studies are designed to test the recombinant BCG's expressing MSP-1 for protection and their abilities to induce a priming immunization that can confer protection upon infection with the malarial parasites. ..
  39. ORAL MALARIA VACCINE DEVELOPMENT--P. BERGHEI MODEL
    Robert Brey; Fiscal Year: 1990
    ..berghei C5 gene, has been expressed and is currently being tested for immunogenicity, preliminary results are presented. If these studIes are successful, analogous oral malaria vaccines could be developed for humans.
  40. Scanning the P. falciparum proteome for vaccine antigens
    Philip Felgner; Fiscal Year: 2006
    ..anti-malaria neutralizing monoclonal human antibodies; 4) development of safe and effective candidate subunit malaria vaccines; and 5) accurate assessment of the quality of the immune responses elicited by alternative malaria vaccines...
  41. EFFECTOR AND MEMORY ANTIMALARIA CD8+ T CELL RESPONSES
    Fidel Zavala; Fiscal Year: 1999
    ..is considered an important goal to be achieved by immunization with subunit or live-vectored candidate malaria vaccines. He proposes to identify parameters which reflect protective antiparasite activity of CD8 T cells; to ..
  42. MEMBRANE ANTIGENS OF P. FALCIPARUM ANTI-GAMETE IMMUNITY
    Nirbhay Kumar; Fiscal Year: 1991
    Malaria remains one of the major health problems in the world. Malaria vaccines are directed against three stages of the parasite: the sporozoites, the merozoites and the sexual forms (gametocytes/gametes)...
  43. Role of Immune Complex in Severe Malarial Anemia
    Jose Stoute; Fiscal Year: 2005
    ..of ICs and CRPs in the pathogenesis of severe malarial anemia, and of the nature of the ICs that form during malaria infection and their implications for the safety of future experimental malaria vaccines in children.
  44. EXPRESSION OF P FALCIPARUM LSA-1 SUBUNITS
    David Clements; Fiscal Year: 2001
    ..There is a great need to control the spread of this disease. Recently, the development of malaria vaccines has focused on the use of recombinant DNA technology...
  45. Novel Adenovirus Vectors for Biodefense Vaccines
    C King; Fiscal Year: 2006
    ..Unfortunately for biodefense, these first non-Ad5 technologies will also be used in the generation of HIV or malaria vaccines. In this application, we propose to develop additional non-Ad5 and non-Ad35 technologies for biodefense ..
  46. Translation Research in Plasmodium vivax
    Socrates Herrera; Fiscal Year: 2005
    ..abstract_text> ..
  47. Global GAS Vaccine Based On The M-Protein
    Michael Good; Fiscal Year: 2008
    ..abstract_text> ..
  48. Immune Pathways as Prerequisites for Adjuvants' Efficacy
    George Hui; Fiscal Year: 2004
    ....
  49. IMMUNOBIOLOGY OF MALARIA GLYCOSYLPHOSPHATIDYLINOSITOL
    Louis Schofield; Fiscal Year: 2001
    ..These areas are central to understanding the host/parasite interaction and the development of effective vaccines to several protozoal pathogens. ..
  50. A CHEMICALLY SYNTHETIC ANTI-TOXIC VACCINE AGAINST MALARI
    Louis Schofield; Fiscal Year: 2002
    ..Clinical immunity to malaria is acquired considerably earlier than anti-parasite immunity, and it is possible that this is mediated by anti-toxin mechanisms. ..
  51. Immunologic interaction of schistomiasis & acute malaria
    Kirsten Lyke; Fiscal Year: 2005
    ..abstract_text> ..
  52. Adherence of malaria-infected red cells
    Alan Cowman; Fiscal Year: 2009
    ..These studies will contribute to and increased understanding of the pathophysiology of falciparum malaria. ..
  53. Potency of cryopreserved, irradiated sporozoite vaccine
    Stephen Hoffman; Fiscal Year: 2005
    ..The project will also provide a method for cryopreserving unirradiated sporozoites that could be used to challenge volunteers by injection with P. falciparum in vaccine studies worldwide. ..
  54. LIVER MEMORY CD8 T CELLS IN PROTECTION TO MALARIA
    Urszula Krzych; Fiscal Year: 2009
    ..abstract_text> ..
  55. Plasmodium carbohydrate receptors in Anopheles gambiae
    RHOEL DAVID DINGLASAN; Fiscal Year: 2008
    ..This line of experimentation will open up new avenues of research through the basic, glycobiological analysis of the mosquito midgut biology. [unreadable] [unreadable] [unreadable]..
  56. Genetically Attenuated Malaria Sporozote Vaccine
    Stephen Hoffman; Fiscal Year: 2008
    ..Success in this project has the potential to lead to development of a safe, effective, attenuated malaria vaccine. [unreadable] [unreadable] [unreadable]..
  57. Lyophilization of Plasmodium falciparum sporozoite vaccine
    Stephen Hoffman; Fiscal Year: 2007
    ..Additionally, a dried vaccine may accelerate a concerted world-wide effort to eradicate this devastating disease. [unreadable] [unreadable] [unreadable]..
  58. Evaluation of High-Capacity Adenovectors in the Eye
    Joseph Bruder; Fiscal Year: 2006
    ..The long-term goal of this proposal is the clinical testing and commercialization of PEDF expressing HC vector for the treatment of AMD and other ocular neovascular diseases. [unreadable] [unreadable]..
  59. MATERNAL MALARIA--PARASITE ADHESION AND ANTIBODIES
    Patrick Duffy; Fiscal Year: 2001
    ..Further, the delineation of binding domains and B cell epitopes will provide the basis to design an anti-adhesion vaccine to protect primigravid and other women susceptible to placental infection with the CSA-binding parasites. ..
  60. Pathogenesis of falciparum malaria in infancy
    Patrick Duffy; Fiscal Year: 2004
    ..Identifying new therapies for children is an urgent public health goal, but is not a funding priority for the United States Department of Defense. ..